This targeted binding allows anti-NGF antibodies to reduce pain and inflammation while minimizing the risk of autoimmune complications for conditions associated with excessive pain, such as osteoarthritis and rheumatoid arthritis [245]. The gene discussed is NGF; the disease is rheumatoid arthritis.